Biological Products, (No Diagnostic Substances)
Standard Industrial Classification: SIC 2836
Industry Insider Sentiment Analysis
The Biological Products, (No Diagnostic Substances) sector (SIC 2836) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-22 20:05 | 2026-05-21 | GLUE | Monte Rosa Therapeutics, Inc. | Manning Anthony M. | Director | OPT+S | $18.01 | 10,000 | $180,100 | 0 |
| 2026-05-22 20:05 | 2026-05-20 | ACOG | Alpha Cognition Inc. | Opaleye Management Inc. | 10% owner | BUY | $5.77 | 24,376 | $140,545 | 2,530,369 |
| 2026-05-22 23:47 | 2026-05-20 | KLRS | Kalaris Therapeutics, Inc. | AKKARAJU SRINIVAS | Director, 10% owner | BUY | $4.83 | 244,300 | $1,179,969 | 2,224,147 |
| 2026-05-22 23:00 | 2026-05-21 | MRNA | Moderna, Inc. | AFEYAN NOUBAR | Director | OPT+S | $46.84 | 9,263 | $433,879 | 3,924 |
| 2026-05-22 21:01 | 2026-05-20 | EXEL | EXELIXIS, INC. | Haley Patrick J. | Officer | SELL | $49.81 | 32,110 | $1,599,399 | 357,638 |
| 2026-05-22 20:03 | 2026-05-20 | IMVT | Immunovant, Inc. | Gloria Melanie | Officer | SELL | $32.45 | 3,115 | $101,072 | 242,107 |
| 2026-05-21 20:20 | 2026-05-19 | COAG | Hemab Therapeutics Holdings, Inc. | RA CAPITAL MANAGEMENT, L.P. | 10% owner | BUY | $24.96 | 4,798 | $119,776 | 6,376,968 |
| 2026-05-21 21:49 | 2026-05-19 | NBIX | NEUROCRINE BIOSCIENCES INC | GORMAN KEVIN CHARLES | Director | OPT+S | $154.33 | 245,088 | $37,824,872 | 511,293 |
| 2026-05-21 22:14 | 2026-05-19 | BCDA | BioCardia, Inc. | Altman Peter | Director, Officer | BUY | $0.92 | 1,700 | $1,570 | 293,266 |
| 2026-05-21 20:01 | 2026-05-20 | FATE | FATE THERAPEUTICS INC | Valamehr Bahram | Director, Officer | SELL | $1.88 | 28,946 | $54,482 | 635,762 |
| 2026-05-21 20:02 | 2026-05-20 | FATE | FATE THERAPEUTICS INC | TAHL CINDY | Officer | SELL | $1.88 | 25,590 | $48,084 | 628,155 |
| 2026-05-20 20:30 | 2026-05-18 | LXEO | Lexeo Therapeutics, Inc. | Otero Jose Manuel | Officer | SELL | $5.07 | 1,302 | $6,606 | 130,088 |
| 2026-05-20 20:30 | 2026-05-18 | LXEO | Lexeo Therapeutics, Inc. | Townsend Richard Nolan | Director, Officer | SELL | $5.06 | 3,342 | $16,927 | 336,764 |
| 2026-05-21 01:22 | 2026-05-20 | IMVT | Immunovant, Inc. | Pande Atul | Director | OPT+S | $32.00 | 6,000 | $192,000 | 116,731 |
| 2026-05-20 23:13 | 2026-05-18 | ADPT | Adaptive Biotechnologies Corp | PISKEL KYLE | Officer | SELL | $13.04 | 3,115 | $40,620 | 256,725 |
| 2026-05-20 21:24 | 2026-05-18 | ATRA | Atara Biotherapeutics, Inc. | Grant-Huerta Yanina | Officer | SELL | $9.13 | 2,414 | $22,036 | 49,636 |
| 2026-05-20 21:24 | 2026-05-18 | ATRA | Atara Biotherapeutics, Inc. | Nguyen AnhCo | Director, Officer | SELL | $9.13 | 5,241 | $47,845 | 137,837 |
| 2026-05-20 20:30 | 2026-05-18 | HUMA | Humacyte, Inc. | Parikh Shamik J | Officer | SELL | $0.90 | 45,887 | $41,147 | 272,713 |
| 2026-05-20 20:31 | 2026-05-18 | HUMA | Humacyte, Inc. | Sander Dale A. | Officer | SELL | $0.90 | 45,887 | $41,147 | 267,213 |
| 2026-05-20 20:32 | 2026-05-18 | HUMA | Humacyte, Inc. | Constantino Michael T. | Director | BUY | $0.89 | 11,000 | $9,840 | 43,950 |
| 2026-05-20 20:33 | 2026-05-19 | HUMA | Humacyte, Inc. | Sebelius Kathleen | Director | BUY | $0.88 | 56,818 | $50,000 | 148,025 |
| 2026-05-20 20:15 | 2026-05-18 | REPL | Replimune Group, Inc. | Hill Emily Luisa | Officer | SELL | $5.08 | 7,812 | $39,685 | 236,556 |
| 2026-05-20 20:15 | 2026-05-18 | REPL | Replimune Group, Inc. | Patel Sushil | Director, Officer | SELL | $5.08 | 37,324 | $189,606 | 747,492 |
| 2026-05-20 20:16 | 2026-05-18 | REPL | Replimune Group, Inc. | Astley-Sparke Philip | Director | SELL | $5.08 | 17,657 | $89,698 | 1,412,414 |
| 2026-05-20 20:16 | 2026-05-18 | REPL | Replimune Group, Inc. | Sarchi Christopher | Officer | SELL | $5.08 | 8,626 | $43,820 | 192,962 |
| 2026-05-20 20:17 | 2026-05-18 | REPL | Replimune Group, Inc. | Schwendenman Andrew | Officer | SELL | $5.08 | 7,894 | $40,102 | 107,057 |
| 2026-05-20 20:18 | 2026-05-18 | REPL | Replimune Group, Inc. | Xynos Konstantinos | Officer | SELL | $5.08 | 14,023 | $71,237 | 235,662 |
| 2026-05-19 20:07 | 2026-05-18 | BCRX | BIOCRYST PHARMACEUTICALS INC | McKee Amy E | Director | SELL | $8.97 | 11,180 | $100,285 | 31,252 |
| 2026-05-19 20:05 | 2026-05-15 | ACOG | Alpha Cognition Inc. | Opaleye Management Inc. | 10% owner | BUY | $5.76 | 34,043 | $196,009 | 2,505,993 |
| 2026-05-20 01:50 | 2026-05-19 | ARTV | Artiva Biotherapeutics, Inc. | Aslan Fred | Director, Officer | SELL | $9.01 | 27,116 | $244,253 | 1,535,082 |
| 2026-05-20 01:50 | 2026-05-19 | ARTV | Artiva Biotherapeutics, Inc. | Banerjee Subhashis | Officer | SELL | $9.01 | 7,037 | $63,386 | 144,963 |
| 2026-05-20 01:51 | 2026-05-19 | ARTV | Artiva Biotherapeutics, Inc. | Bush Jennifer | Officer | SELL | $9.01 | 8,790 | $79,179 | 337,920 |
| 2026-05-20 01:52 | 2026-05-19 | ARTV | Artiva Biotherapeutics, Inc. | Horan Christopher | Officer | SELL | $9.01 | 7,002 | $63,073 | 293,450 |
| 2026-05-20 01:52 | 2026-05-19 | ARTV | Artiva Biotherapeutics, Inc. | Raymon Heather | Officer | SELL | $9.01 | 3,095 | $27,879 | 148,228 |
| 2026-05-20 01:05 | 2026-05-19 | MGTX | MeiraGTx Holdings plc | Forbes Alexandria | Director, Officer | SELL | $9.17 | 62,000 | $568,540 | 1,387,695 |
| 2026-05-19 23:06 | 2026-05-18 | TNYA | Tenaya Therapeutics, Inc. | Higa Tomohiro | Officer | SELL | $0.79 | 1,485 | $1,178 | 118,267 |
| 2026-05-19 23:09 | 2026-05-18 | TNYA | Tenaya Therapeutics, Inc. | Tingley Whittemore | Officer | SELL | $0.79 | 3,121 | $2,477 | 215,497 |
| 2026-05-19 23:09 | 2026-05-18 | TNYA | Tenaya Therapeutics, Inc. | Ali Faraz | Director, Officer | SELL | $0.79 | 3,390 | $2,690 | 440,014 |
| 2026-05-19 22:58 | 2026-05-18 | EXEL | EXELIXIS, INC. | Hefti Brenda | Officer | SELL | $50.21 | 6,625 | $332,641 | 106,762 |
| 2026-05-19 22:58 | 2026-05-18 | EXEL | EXELIXIS, INC. | Senner Christopher J. | Officer | SELL | $50.00 | 34,901 | $1,745,050 | 952,317 |
| 2026-05-19 21:02 | 2026-05-19 | ACOG | Alpha Cognition Inc. | D'Angelo Lauren | Officer | BUY | $5.76 | 3,500 | $20,160 | 140,695 |
| 2026-05-18 20:57 | 2026-05-15 | MRNA | Moderna, Inc. | Hoge Stephen | Officer | OPT+S | $48.40 | 53,336 | $2,581,462 | 1,477,997 |
| 2026-05-18 21:07 | 2026-05-15 | MAZE | Maze Therapeutics, Inc. | Coloma Jason V | Director, Officer | SELL | $26.00 | 1,938 | $50,388 | 31,001 |
| 2026-05-18 21:50 | 2026-05-15 | GILD | GILEAD SCIENCES, INC. | Dickinson Andrew D | Officer | SELL | $132.27 | 3,000 | $396,810 | 173,191 |
| 2026-05-18 21:50 | 2026-05-15 | NBIX | NEUROCRINE BIOSCIENCES INC | POPS RICHARD F | Director | OPT+S | $157.65 | 15,000 | $2,364,761 | 34,480 |
| 2026-05-19 00:20 | 2026-05-18 | BCDA | BioCardia, Inc. | Altman Peter | Director, Officer | BUY | $0.92 | 5,700 | $5,244 | 291,566 |
| 2026-05-18 21:45 | 2026-05-15 | GILD | GILEAD SCIENCES, INC. | Mercier Johanna | Officer | OPT+S | $131.29 | 28,000 | $3,676,198 | 125,779 |
| 2026-05-18 21:03 | 2026-05-14 | MAZE | Maze Therapeutics, Inc. | Bernstein Harold | Officer | OPT+S | $26.22 | 15,000 | $393,354 | 0 |
| 2026-05-18 12:03 | 2026-05-14 | CVM | CEL SCI CORP | KERSTEN GEERT R | Director, Officer | BUY | $1.20 | 300,000 | $360,000 | 311,547 |
| 2026-05-15 20:08 | 2026-05-13 | BCRX | BIOCRYST PHARMACEUTICALS INC | Barnes Alane P | Officer | OPT+S | $9.54 | 62,500 | $596,250 | 400,703 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Biological Products, (No Diagnostic Substances) sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2836) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Biological Products, (No Diagnostic Substances)
Every transaction in the Biological Products, (No Diagnostic Substances) industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.